http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 16:55:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protara+Therapeutics%2C+++++For%3A+Jun+02++Filed+by%3A+CONKLING+WILLIAM/26599966.html si-local-file:///var/storage/secattach/20260603/26599966.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protara+Therapeutics%2C+++++For%3A+Jun+02++Filed+by%3A+CONKLING+WILLIAM/26599966.html Wed, 03 Jun 2026 16:55:00 -0400 O.02411061 TARA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protara+Therapeutics%2C+++++For%3A+Jun+02++Filed+by%3A+CONKLING+WILLIAM/26599966.html si-local-file:///var/storage/secattach/20260603/26599966.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protara+Therapeutics%2C+++++For%3A+Jun+02++Filed+by%3A+CONKLING+WILLIAM/26599966.html Wed, 03 Jun 2026 16:55:00 -0400 O.02411061 TARA http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Protara+Therapeutics%2C++++++++++++++++/26567929.html si-local-file:///var/storage/secattach/20260528/26567929.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Protara+Therapeutics%2C++++++++++++++++/26567929.html Thu, 28 May 2026 16:31:00 -0400 O.02411061 TARA http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Protara+Therapeutics%2C++++++++++++++++/26567929.html si-local-file:///var/storage/secattach/20260528/26567929.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Protara+Therapeutics%2C++++++++++++++++/26567929.html Thu, 28 May 2026 16:31:00 -0400 O.02411061 TARA http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Protara+Therapeutics%2C++++++++++++++++/26545240.html si-local-file:///var/storage/secattach/20260526/26545240.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Protara+Therapeutics%2C++++++++++++++++/26545240.html Tue, 26 May 2026 06:03:00 -0400 O.02411061 TARA http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Protara+Therapeutics%2C++++++++++++++++/26545240.html si-local-file:///var/storage/secattach/20260526/26545240.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Protara+Therapeutics%2C++++++++++++++++/26545240.html Tue, 26 May 2026 06:03:00 -0400 O.02411061 TARA http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html <p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA on Tuesday, May 26, 2026, at 9:30 am ET.</p> <p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=R89xlK0-S6jhfp4KiJ53V7mqWTem_MjiBqlGMwOkyDUDeioVkP8lZosL4EemtgcNAMzKfPDrO1tg3NVFlHUjJKwTp8N9SJIcJi6djhaelIE=" rel="nofollow" target="_blank">https://ir.protaratx.com</a>. The webcast will be archived for a limited time following the http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html Wed, 20 May 2026 08:00:00 -0400 A.50100012 O.02411061 O.07579093 TARA http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html <p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA on Tuesday, May 26, 2026, at 9:30 am ET.</p> <p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=R89xlK0-S6jhfp4KiJ53V7mqWTem_MjiBqlGMwOkyDUDeioVkP8lZosL4EemtgcNAMzKfPDrO1tg3NVFlHUjJKwTp8N9SJIcJi6djhaelIE=" rel="nofollow" target="_blank">https://ir.protaratx.com</a>. The webcast will be archived for a limited time following the http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html Wed, 20 May 2026 08:00:00 -0400 A.50100012 O.02411061 O.07579093 TARA http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html <p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA on Tuesday, May 26, 2026, at 9:30 am ET.</p> <p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=R89xlK0-S6jhfp4KiJ53V7mqWTem_MjiBqlGMwOkyDUDeioVkP8lZosL4EemtgcNAMzKfPDrO1tg3NVFlHUjJKwTp8N9SJIcJi6djhaelIE=" rel="nofollow" target="_blank">https://ir.protaratx.com</a>. The webcast will be archived for a limited time following the http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html Wed, 20 May 2026 08:00:00 -0400 A.50100012 O.02411061 O.07579093 TARA http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html <p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA on Tuesday, May 26, 2026, at 9:30 am ET.</p> <p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=R89xlK0-S6jhfp4KiJ53V7mqWTem_MjiBqlGMwOkyDUDeioVkP8lZosL4EemtgcNAMzKfPDrO1tg3NVFlHUjJKwTp8N9SJIcJi6djhaelIE=" rel="nofollow" target="_blank">https://ir.protaratx.com</a>. The webcast will be archived for a limited time following the http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html Wed, 20 May 2026 08:00:00 -0400 A.50100012 O.02411061 O.07579093 TARA http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html <p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA on Tuesday, May 26, 2026, at 9:30 am ET.</p> <p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=R89xlK0-S6jhfp4KiJ53V7mqWTem_MjiBqlGMwOkyDUDeioVkP8lZosL4EemtgcNAMzKfPDrO1tg3NVFlHUjJKwTp8N9SJIcJi6djhaelIE=" rel="nofollow" target="_blank">https://ir.protaratx.com</a>. The webcast will be archived for a limited time following the http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html Wed, 20 May 2026 08:00:00 -0400 A.50100012 O.02411061 O.07579093 TARA http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html <p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA on Tuesday, May 26, 2026, at 9:30 am ET.</p> <p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=R89xlK0-S6jhfp4KiJ53V7mqWTem_MjiBqlGMwOkyDUDeioVkP8lZosL4EemtgcNAMzKfPDrO1tg3NVFlHUjJKwTp8N9SJIcJi6djhaelIE=" rel="nofollow" target="_blank">https://ir.protaratx.com</a>. The webcast will be archived for a limited time following the http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html Wed, 20 May 2026 08:00:00 -0400 A.50100012 O.02411061 O.07579093 TARA http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html <p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA on Tuesday, May 26, 2026, at 9:30 am ET.</p> <p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=R89xlK0-S6jhfp4KiJ53V7mqWTem_MjiBqlGMwOkyDUDeioVkP8lZosL4EemtgcNAMzKfPDrO1tg3NVFlHUjJKwTp8N9SJIcJi6djhaelIE=" rel="nofollow" target="_blank">https://ir.protaratx.com</a>. The webcast will be archived for a limited time following the http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html Wed, 20 May 2026 08:00:00 -0400 A.50100012 O.02411061 O.07579093 TARA http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html <p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA on Tuesday, May 26, 2026, at 9:30 am ET.</p> <p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=R89xlK0-S6jhfp4KiJ53V7mqWTem_MjiBqlGMwOkyDUDeioVkP8lZosL4EemtgcNAMzKfPDrO1tg3NVFlHUjJKwTp8N9SJIcJi6djhaelIE=" rel="nofollow" target="_blank">https://ir.protaratx.com</a>. The webcast will be archived for a limited time following the http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Present+at+the+TD+Cowen+7th+Annual+Oncology+Innovation+Summit%3A+Insights+for+ASCO+%26amp%3B+EHA/26525028.html Wed, 20 May 2026 08:00:00 -0400 A.50100012 O.02411061 O.07579093 TARA http://www.streetinsider.com/Analyst+PT+Change/Protara+Therapeutics+%28TARA%29+PT+Raised+to+%2428+at+Oppenheimer/26524869.html Oppenheimer analyst Leland Gershell raised the price target on Protara Therapeutics (NASDAQ: TARA) to $28.00 (from $25.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Protara+Therapeutics+%28TARA%29+PT+Raised+to+%2428+at+Oppenheimer/26524869.html Wed, 20 May 2026 07:36:55 -0400 TARA http://www.streetinsider.com/Analyst+Comments/Protara+Therapeutics+%28TARA%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald/26524796.html <p>Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Protara Therapeutics (NASDAQ: TARA).</p><p>The analyst commented, "Today's investor webinar of TARA-002 (bacterial immunopotentiator) in lymphatic malformations (LMs) has put all the pieces together for the first time. There are a lot of reasons to like LM now: It's clear that TARA-002 works, and works incredibly well (a functional cure) in macrocystic/mixed cystic LMs. No approved therapy, and no direct competitor also make it a very impactful therapy. The recently aligned regulatory path should support full approval with the current STARBORN-02 trial. Enrollment should be done by YE, and BLA is http://www.streetinsider.com/Analyst+Comments/Protara+Therapeutics+%28TARA%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald/26524796.html Wed, 20 May 2026 07:29:26 -0400 TARA http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Protara+Therapeutics+%28TARA%29/26524522.html <p>H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $27.00 price target on Protara Therapeutics (NASDAQ: TARA).</p><p>The analyst commented: "Yesterday Protara hosted a webinar focused on lymphatic malformations (LMs), providing a more complete picture of the regulatory path, interim STARBORN-1 data, unmet need, and commercial opportunity for TARA-002. In our view, the update reinforces our confidence that LMs represent a key slice of underappreciated value that complements an already exciting NMIBC story for TARA-002. KOL commentary underscored the significant unmet need in macrocystic and mixed cystic LMs, where current approaches including ethanol, bleomycin, doxycycline, other sclerosants, and surgery are http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Protara+Therapeutics+%28TARA%29/26524522.html Wed, 20 May 2026 06:47:45 -0400 TARA http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Host+Virtual+Investor+Webinar+to+Discuss+TARA-002+for+Lymphatic+Malformations+on+Tuesday%2C+May+19%2C+2026/26510445.html <p align="center"><em>Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program</em></p> <p>NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Host+Virtual+Investor+Webinar+to+Discuss+TARA-002+for+Lymphatic+Malformations+on+Tuesday%2C+May+19%2C+2026/26510445.html Mon, 18 May 2026 08:00:00 -0400 O.02411061 TARA http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Host+Virtual+Investor+Webinar+to+Discuss+TARA-002+for+Lymphatic+Malformations+on+Tuesday%2C+May+19%2C+2026/26510445.html <p align="center"><em>Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program</em></p> <p>NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and http://www.streetinsider.com/Press+Releases/Protara+Therapeutics+to+Host+Virtual+Investor+Webinar+to+Discuss+TARA-002+for+Lymphatic+Malformations+on+Tuesday%2C+May+19%2C+2026/26510445.html Mon, 18 May 2026 08:00:00 -0400 O.02411061 TARA http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Host+Virtual+Investor+Webinar+to+Discuss+TARA-002+for+Lymphatic+Malformations+on+Tuesday%2C+May+19%2C+2026/26510445.html <p align="center"><em>Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program</em></p> <p>NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Host+Virtual+Investor+Webinar+to+Discuss+TARA-002+for+Lymphatic+Malformations+on+Tuesday%2C+May+19%2C+2026/26510445.html Mon, 18 May 2026 08:00:00 -0400 O.02411061 TARA http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Host+Virtual+Investor+Webinar+to+Discuss+TARA-002+for+Lymphatic+Malformations+on+Tuesday%2C+May+19%2C+2026/26510445.html <p align="center"><em>Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program</em></p> <p>NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and http://www.streetinsider.com/Globe+Newswire/Protara+Therapeutics+to+Host+Virtual+Investor+Webinar+to+Discuss+TARA-002+for+Lymphatic+Malformations+on+Tuesday%2C+May+19%2C+2026/26510445.html Mon, 18 May 2026 08:00:00 -0400 O.02411061 TARA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Protara+Therapeutics%2C++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502897.html si-local-file:///var/storage/secattach/20260515/26502897.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Protara+Therapeutics%2C++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502897.html Fri, 15 May 2026 12:39:00 -0400 O.02411061 TARA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Protara+Therapeutics%2C++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502897.html si-local-file:///var/storage/secattach/20260515/26502897.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Protara+Therapeutics%2C++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26502897.html Fri, 15 May 2026 12:39:00 -0400 O.02411061 TARA http://www.streetinsider.com/FDA/Protara+reports+12-month+data+for+bladder+cancer+treatment+TARA-002/26499140.html <p>Protara Therapeutics Inc. (NASDAQ: TARA) reported updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer who have not received prior BCG treatment.</p> <p>The company said TARA-002 demonstrated a 72% complete response rate at any time and a 55% complete response rate at the 12-month landmark in BCG-naïve patients. The dataset included 31 patients, with 29 evaluable for efficacy and 20 evaluable at 12 months as of an April 5, 2026 data cutoff.</p> <p>The complete response rate was 67% at six months and 55% at 12 months. Among patients who responded to treatment, 92% http://www.streetinsider.com/FDA/Protara+reports+12-month+data+for+bladder+cancer+treatment+TARA-002/26499140.html Fri, 15 May 2026 07:00:27 -0400 O.02411061 TARA http://www.streetinsider.com/FDA/Protara+reports+12-month+data+for+bladder+cancer+treatment+TARA-002/26499140.html <p>Protara Therapeutics Inc. (NASDAQ: TARA) reported updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer who have not received prior BCG treatment.</p> <p>The company said TARA-002 demonstrated a 72% complete response rate at any time and a 55% complete response rate at the 12-month landmark in BCG-naïve patients. The dataset included 31 patients, with 29 evaluable for efficacy and 20 evaluable at 12 months as of an April 5, 2026 data cutoff.</p> <p>The complete response rate was 67% at six months and 55% at 12 months. Among patients who responded to treatment, 92% http://www.streetinsider.com/FDA/Protara+reports+12-month+data+for+bladder+cancer+treatment+TARA-002/26499140.html Fri, 15 May 2026 07:00:27 -0400 O.02411061 TARA